These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11704968)

  • 21. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD; Levy MC; Schwab GG; Paik Y
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract]   [Full Text] [Related]  

  • 22. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract]   [Full Text] [Related]  

  • 23. Is the information "fair and balanced" in direct-to-consumer prescription drug websites?
    Huh J; Cude BJ
    J Health Commun; 2004; 9(6):529-40. PubMed ID: 15764451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deterring the importation of counterfeit pharmaceutical products.
    Stearn DW
    Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
    [No Abstract]   [Full Text] [Related]  

  • 25. Can speech by FDA-regulated firms ever be noncommercial?
    Cortez N
    Am J Law Med; 2011; 37(2-3):388-421. PubMed ID: 21847886
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug and device litigation in the 21st century.
    Svitak LS; Goss PJ
    Spec Law Dig Health Care Law; 2001 Nov; (271):9-36. PubMed ID: 11802352
    [No Abstract]   [Full Text] [Related]  

  • 27. In Opposition to Liberty: We Need a "Sovereign" to Govern Drug Claims.
    Avorn J
    Ann Intern Med; 2015 Aug; 163(3):229-30. PubMed ID: 26121615
    [No Abstract]   [Full Text] [Related]  

  • 28. Inconsistent government policies: why FDA off-label regulation cannot survive First Amendment review under Greater New Orleans.
    Hall RF; Sobotka E
    Food Drug Law J; 2007; 62(1):1-48. PubMed ID: 17444025
    [No Abstract]   [Full Text] [Related]  

  • 29. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 30. Commentary: can we talk? About Food and Drug Regulation and the First Amendment.
    Cohen MN
    Food Drug Law J; 2003; 58(4):741-56. PubMed ID: 15027458
    [No Abstract]   [Full Text] [Related]  

  • 31. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

  • 32. The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals.
    Greene JA; Watkins ES
    N Engl J Med; 2015 Sep; 373(12):1087-9. PubMed ID: 26287749
    [No Abstract]   [Full Text] [Related]  

  • 33. Advertising medicines to the public.
    George CF
    J R Coll Physicians Lond; 1996; 30(2):102-3. PubMed ID: 8709051
    [No Abstract]   [Full Text] [Related]  

  • 34. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 35. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 36. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 37. MedGuide: at last a long-sought opportunity for patient education about prescription drugs.
    Marwick C
    JAMA; 1997 Mar; 277(12):949-50. PubMed ID: 9091654
    [No Abstract]   [Full Text] [Related]  

  • 38. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 39. Maine law requires drug companies to provide clinical trial data.
    Appell D
    J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043
    [No Abstract]   [Full Text] [Related]  

  • 40. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.